

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

PASSING AWAY OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”) announces with the deepest sorrow that Mr. Lianming HE (“**Mr. He**”), an independent non-executive director, the chairman of the remuneration committee and a member of the audit committee and nomination committee of the Company, passed away on March 30, 2022.

The late Mr. He was appointed as an independent non-executive director of the Company in June 2020 and had made valuable contributions during his tenure of office. The Board would like to express sincere gratitude to Mr. He for his dedication and convey their condolences to his family.

Following the passing away of Mr. He, there is a vacancy in each of the position of chairman of the remuneration committee and member of the audit committee and nomination committee of the Company, and the Company has only two independent non-executive directors, thus the number of the independent non-executive directors of the Company does not satisfy (i) the minimum number as required under Rule 3.10(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); (ii) the requirement that independent non-executive directors must represent at least one-third of the board as required under Rule 3.10A of the Listing Rules; (iii) the requirement that the audit committee must comprise a minimum of three members as required under Rule 3.21 of the Listing Rules; (iv) the requirement that the remuneration committee must be chaired by an independent non-executive director as required under Rule 3.25 of the Listing Rules; and (v) the requirement under Rule 3.27A of the Listing Rules which stipulates that the nomination committee must comprise a majority of independent non-executive directors.

The Company will identify a suitable candidate to fill the vacancy of independent non-executive director in order to fulfil the requirements of the Listing Rules as soon as practicable and in any event within three months from March 30, 2022 pursuant to Rules 3.11, 3.21, 3.23, 3.25 and 3.27 of the Listing Rules. Further announcement will be made by the Company in relation to the above as and when appropriate.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, March 31, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU and Mr. Yiran HUANG as independent non-executive directors.